Emtora Biosciences

Emtora Biosciences is a clinical-stage life science company based in San Antonio, Texas, USA, developing eRapa, a novel microencapsulated formulation of rapamycin designed to prevent cancer onset and recurrence. Founded in late 2012 as Rapamycin Holdings by developers Z David Sharp and Randy Strong, the privately held firm licenses its innovative technology from UT Health San Antonio. The organization targets oncology, immunology, neurology, and trauma applications with improved drug delivery, lower dosing, and significantly reduced toxicity. Advancing its therapeutic pipeline toward commercialization, the biotechnology enterprise has secured multiple issued patents, launched research products, and completed a Phase 1b trial in low-grade prostate cancer patients. Under chief executive officer Carole Spangler Vaughn, the rebranded company secured a $3 million grant from the Cancer Prevention Research Institute of Texas to fund familial adenomatous polyposis clinical trials.